Balloon-TACE Efficacy

Since the first particle-based tumor embolization in the early 1970's, embolization agents have improved dramatically. Over the same period, development of devices capable of delivering complete tumor fill have been lacking, even though tumor fill is the single most important factor in achieving a CR[1,2]. Sniper® is a superselective delivery device that improves tumor fill and associated complete response at the first procedure. **The efficacy of Balloon-TACE (B-TACE) is remarkable.**

On Average, Balloon-TACE Improves CR on the First Procedure by 1.5X

Eight Clinical Studies with 941 Patients are Presented Below

2-Arm Studies, Balloon vs Standard Microcatheter

Golfieri, 2021[3]
Multi Center, 2-Arm Retrospective
530 patients (p = 0.026)
B-cTACE/B- DEB-TACE Improve CR by 40%
Retreatment Rate at 6 months:
B-TACE 10%, Standard Micro 22% (120% Better)

Irie, 2016[4]
2-Arm Retrospective
77 patients, p = 0.016
B-cTACE Improves CR by 37%
100% Objective Response
5 Year Survival Improved by 53%

Arai, 2015[5]
2-Arm Retrospective,
97 patients (p < 0.05)
B-cTACE Improves CR by 39%
Disease Progression Reduced from 25% to 4%

Lucatelli, 2021[6]
2-Arm Retrospective
97 patients (p < 0.05)
B-DEB-TACE Improves CR by 39%

Ogawa, 2016[7]
2-Arm Retrospective
61 patients (p = 0.035)
B-cTACE Improves CR by 81%



1-Arm Studies

Lee, Madoff, 2021
1-Arm Retrospective, 31 patients
74% CR, 95% OR (p < 0.05)
100% Disease Control

Lucatelli, 2019
1-Arm Retrospective B-DEB-TACE, 22 patients
44% CR (p < 0.05)
100% Objective Response

Goldman, Fischman, 2018
1-Arm Retrospective, 26 patients
60% CR (p < 0.05)
100% Disease Control

Summary

Eight B-TACE Clinical Studies, including almost 1000 patients from the US, Japan & Italy are **consistent in demonstrating a remarkable rate of complete response at the first procedure that is 1.5 times better than a standard microcatheter.** This is prognostic for a > 50% improvement in 5-year survival[8] which was also demonstrated by Irie, 2016[4].

Embolx, Inc.
Haley McGregor, hmcgregor@embolx.com

References

1. **Kim DY**, Ryu HJ, Choi JY, Park JY, Lee DY, Kim BK, Ahn SH, Chon CY, Han KH. Radiological response predicts survival following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics (2012) 35:1343-1350.
2. **Miyayama S**, Matsui O, Yamashiro M, Ryu Y, Kaito K, Ozaki K, Takeda T, Yoneda N, Notsumata K, Toya D, Tanaka N, Mitsui T Ultraselective transcatheter arterial chemoembolization with a 2-f tip microcatheter for small hepatocellular carcinomas: relationship between tumor recurrence and visualization of the portal vein with iodized oil (2007).
3. **Golfieri R**, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A. Cardio Intervent Radiol (2021) https://doi.org/10.1007/s00270-021-02805-5.
4. **Irie T**, Kuramochi M, Kamoshida T, Takahashi N. Selective balloon-occluded transarterial chemoembolization for patients with one or two hepatocellular carcinoma nodules: retrospective comparison with conventional super-selective TACE. Hepatology Research (2016) 46:209-214.
5. **Arai H**, Abe T, Takayama H, et al. Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatology Research (2015) 45: 663-666.
6. **Lucatelli P**, De Rubeis G, Rocco B, Basilico F, Cannavale A, et al. Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study. BMC Gastroenterology (2021) 21:55 1-9.
7. **Ogawa M**, Takayasu K, Hirayama M, et al. Efficacy of a microballoon catheter in transarterial chemoembolization using miriplatin, a lipophilic anticancer drug: short-term results. Hepatology Research (2016) 46: E60-69.
8. **Lee KS**, Madoff DC. Segmental balloon-occluded transarterial chemoembolization of hepatocellular carcimoma. SIR 2021, Abstract.
9. **Lucatelli, P**, Corradini LG, De Rubeis G, Rocco B, Bassilico R, Cannavale A, et al. Balloon-occluded transcatheter arterial chemoembolization (b-TACE) for hepatocellular carcinoma performed with polyethylene-glycol epirubicin-loaded drug-elution embolics: safety and preliminary results. Cardiovasc Intervent Radiol (2019) 42:853-862.
10. **Goldman D**, Singh M, Patel R, et al. Balloon-Occluded Transarterial Chemoembolization (B-TACE) for the Treatment of Hepatocellular Carcinoma: A Single Center U.S. Preliminary Experience. J Vasc Interv Radiol (2019) 30:342–346.